1. Home
  2. IFRX vs BHST Comparison

IFRX vs BHST Comparison

Compare IFRX & BHST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IFRX
  • BHST
  • Stock Information
  • Founded
  • IFRX 2007
  • BHST 2007
  • Country
  • IFRX Germany
  • BHST Canada
  • Employees
  • IFRX N/A
  • BHST N/A
  • Industry
  • IFRX Biotechnology: Pharmaceutical Preparations
  • BHST
  • Sector
  • IFRX Health Care
  • BHST
  • Exchange
  • IFRX Nasdaq
  • BHST Nasdaq
  • Market Cap
  • IFRX 117.8M
  • BHST 106.0M
  • IPO Year
  • IFRX 2017
  • BHST N/A
  • Fundamental
  • Price
  • IFRX $1.05
  • BHST $6.49
  • Analyst Decision
  • IFRX Strong Buy
  • BHST Strong Buy
  • Analyst Count
  • IFRX 2
  • BHST 2
  • Target Price
  • IFRX $9.00
  • BHST $13.00
  • AVG Volume (30 Days)
  • IFRX 356.5K
  • BHST 10.2K
  • Earning Date
  • IFRX 03-20-2025
  • BHST 03-31-2025
  • Dividend Yield
  • IFRX N/A
  • BHST N/A
  • EPS Growth
  • IFRX N/A
  • BHST N/A
  • EPS
  • IFRX N/A
  • BHST N/A
  • Revenue
  • IFRX $171,642.00
  • BHST $25,188,000.00
  • Revenue This Year
  • IFRX $381.73
  • BHST $161.11
  • Revenue Next Year
  • IFRX $2,277.23
  • BHST $64.74
  • P/E Ratio
  • IFRX N/A
  • BHST N/A
  • Revenue Growth
  • IFRX 162.79
  • BHST 98.77
  • 52 Week Low
  • IFRX $1.01
  • BHST $0.00
  • 52 Week High
  • IFRX $2.82
  • BHST $7.38
  • Technical
  • Relative Strength Index (RSI)
  • IFRX 31.57
  • BHST N/A
  • Support Level
  • IFRX $1.16
  • BHST N/A
  • Resistance Level
  • IFRX $1.30
  • BHST N/A
  • Average True Range (ATR)
  • IFRX 0.12
  • BHST 0.00
  • MACD
  • IFRX 0.02
  • BHST 0.00
  • Stochastic Oscillator
  • IFRX 9.76
  • BHST 0.00

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

About BHST BioHarvest Sciences Inc. Common Stock

BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.

Share on Social Networks: